This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Smith & Nephew Launches Regranex360™ - A New Support Network For Patients Using REGRANEX® (becaplermin) Gel, 0.01%

FORT WORTH, Texas, Oct. 8, 2013 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of Regranex 360 , a comprehensive new program to support patients in the U.S. using REGRANEX Gel. REGRANEX Gel is the first and only FDA-approved platelet-derived growth factor (PDGF) therapy indicated as an adjunct to good ulcer care for the treatment of lower extremity diabetic neuropathic ulcers. 1

"We are very pleased to introduce the Regranex 360 program as part of our ongoing commitment to offer evidence-based biologic therapeutics along with best-in-class provider and patient support programs to the wound care market," said Rob Bancroft, President of Smith & Nephew Biotherapeutics. "In particular, we are delighted to streamline and enhance the REGRANEX Gel patient experience with a program designed to help each individual stay on track with their treatment."

Regranex 360 is a full service online portal designed to simplify the prior authorization and product acquisition process. In addition, to promote compliance and adherence to REGRANEX Gel, Regranex 360 provides each patient with a care coordinator they can contact via phone throughout their entire course of therapy.

Regranex 360 is simple to use and access. Clinicians submit enrollment forms either through or via fax. Regranex 360 then obtains prior authorization approval and forwards the prescription to an appropriate pharmacy. A patient care coordinator will contact the patient to schedule delivery, provide education and answer any questions about treatment. Patients can also contact the Regranex 360 hotline with any questions during their course of therapy. is available to prescribers and patients 24 hours a day, 7 days a week; the hotline, 1-888-REGRANEX (734-7263) is accessible Monday through Friday, 8:00am to 7:00pm EST.

In addition to the Regranex 360 program, Smith & Nephew Biotherapeutics has also launched a new REGRANEX Gel Web site ( that highlights features of the product, including clinical research, provides a dosing calculator and offers additional tips for patients.

Important Safety Information

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 -0.76%
FB $101.00 1.47%
GOOG $684.12 0.89%
TSLA $143.67 -3.09%
YHOO $27.10 1.04%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs